Drug Profile
COL7A1 encoding stem cell therapy - Holostem Terapie Avanzate
Alternative Names: ATMP - Holostem Terapie Avanzate; Hologene-7Latest Information Update: 24 Feb 2022
Price :
$50
*
At a glance
- Originator Holostem Terapie Avanzate
- Class Gene therapies; Stem cell therapies
- Mechanism of Action Cell replacements; Collagen type VII replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Epidermolysis bullosa dystrophica
Most Recent Events
- 15 Feb 2022 Holostem Terapie Avanzate terminates phase I/II HOLOGENE7 trial in Epidermolysis bullosa dystrophica (In children, In adults, In adolescents) in Austria (Intradermal) due to replacement of the trial by a new trial in progress (NCT02984085) (EudtaCT2015-004592-74)
- 29 Oct 2021 Phase-I/II clinical trials ongoing in Epidermolysis bullosa dystrophica (In children, In adults, In adolescents) in Austria (Intradermal) (NCT02984085) (EudtaCT2015-004592-74)
- 30 Jul 2020 Holostem Terapie Avanzate completes enrolment in its phase I/II HOLOGENE7 trial for Epidermolysis bullosa dystrophica (In children, In adults, In adolescents) in Austria (Intradermal) (NCT02984085) (EudtaCT2015-004592-74)